ESG News For Alnylam Pharmaceuticals, Inc.

– Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint–– Expanded Alnylam Challengers Global Health Equity Initiative –

–Report Features New Disclosures of Company’s Impact on Planet—Including Scope 1, 2, and Select Scope 3 Greenhouse Gas (GHG) Emissions–– Aligns with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) Reporting Frameworks –

– Alnylam Supports 23 Local Organizations in the Greater Boston Area and Western Europe –